drugset / Trial / NCT00537420

A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

NCT00537420

Phase 2 Completed 551 enrolled Nastech Pharmaceutical Company, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine the effect of nasal PYY3-36 on weight loss post 24 weeks of treatment.

Timeline

Start
2007-10
Primary completion
2008-07
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject PEPTIDE YY HUMAN (3-36) Peptide 200 ug Intranasal
Subject PEPTIDE YY HUMAN (3-36) Peptide 400 ug Intranasal
Subject PEPTIDE YY HUMAN (3-36) Peptide 600 ug Intranasal
Comparator Sibutramine Small molecule 10 mg

Indications